Stock News and Filings Feed


Add TBP
to your dashboard

Tetra Bio-Pharma to engage in co-development and distribution partnership with major healthcare specialty distributor

2017-09-20 marketwired
OTTAWA, ONTARIO--(Marketwired - Sept. 20, 2017) - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE:TBP)(OTCQB:TBPMF), today announced that it has signed a letter of intent (LOI) with a major player of the healthcare specialty industry. (3-0)

Tetra Bio-Pharma getting ready to file a clinical trial application to initiate phase 3 clinical trial on terminal cancer patients in the coming weeks

2017-09-18 marketwired
OTTAWA, ONTARIO--(Marketwired - Sept. 18, 2017) - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE:TBP)(OTCQB:TBPMF), today announces that it will be filing a clinical trial application (CTA) in the coming weeks to therapeutic products directorate (TPD) to initiate its Phase 3 clinical trial of PPP001 in terminal cancer patients. With this filing, Tetra expects to be on time with its previously announced schedule with the development of PPP001. (3-0)

Tetra Bio-Pharma Announces Approval to List on the TSX Venture Exchange

2017-08-16 marketwired
OTTAWA, ONTARIO--(Marketwired - Aug. 16, 2017) - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(TSX VENTURE:TBP)(OTCQB:TBPMF), today announced that its common shares have been approved for trading on the TSX Venture Exchange and that it has applied for voluntary delisting of its common shares from the Canadian Securities Exchange (CSE). Tetra's shares will commence trading on the TSX Venture on the opening of markets on Wednesday, August 16, 2017, under the symbol "TBP".

University of New Brunswick announces cannabis research chair

2017-08-09 globalnews.ca
The University of New Brunswick has announced the university will have a Cannabis Health Research Chair.

Tetra Bio-Pharma CSO Discusses Opportunities in Exclusive CFN Media Interview

2017-07-26 marketwired
SEATTLE, WA--(Marketwired - Jul 26, 2017) -  CFN Media Group ("CannabisFN"), the leading creative agency and digital media network dedicated to legal cannabis, announces the publication of an article and exclusive interview covering Tetra Bio-Pharma Inc. (CSE: TBP) (CSE: TBP.CN) (CNSX: TBP) (OTCQB: TBPMF). The interview, with Chief Science Officer Dr. Guy Chamberland, and article discuss the company's progress in advancing its clinical pipeline designed to bring innovative cannabis products to market.

Tetra Bio-Pharma Announces Stock Option Grant to CEO

2017-07-25 marketwired
OTTAWA, ONTARIO--(Marketwired - July 25, 2017) - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(OTCQB:TBPMF), announces that it has made a grant of stock options under its stock option plan to the newly appointed Chief Executive Officer, Bernard Fortier to acquire a total of 400,000 common shares of the Company. All of the options are exercisable at a price of $0.80 per share.

Tetra Bio-Pharma Accelerates Growth Strategy with Appointment of Bernard Fortier as CEO

2017-07-24 marketwired
OTTAWA, ONTARIO--(Marketwired - July 24, 2017) - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(OTCQB:TBPMF) today announced that it has strengthened its management team with the appointment of Bernard Fortier to the position of Chief Executive Officer, effective today, July 24, 2017. Mr. Andre Rancourt, previous interim CEO will take the position as Chairman of the Board of Directors.

Tetra Bio-Pharma Signs Letter of Intent with Constance Therapeutics

2017-07-19 marketwired
OTTAWA, ONTARIO--(Marketwired - July 19, 2017) - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(OTCQB:TBPMF), announced today it has signed a Letter of Intent (LOI) with Constance Therapeutics, Inc. of San Francisco, California, USA, for the clinical development and commercialization in Canada of its signature standardized, patent-pending, medicinal cannabis extract products.

Tetra Bio-Pharma Announces Results of Voting at Annual Shareholders' Meeting & Provides a Corporate Update

2017-07-11 marketwired
OTTAWA, ONTARIO--(Marketwired - July 11, 2017) - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(OTCQB:TBPMF), is pleased to announce the results of the vote at its July 10, 2017 annual shareholders' meeting.

CORRECTION - Tetra Bio-Pharma: Defending & Validating Smoked Cannabis -- CFN Media

2017-07-06 marketwired
SEATTLE, WA--(Marketwired - Jul 6, 2017) - In the news release, "Tetra Bio-Pharma: Defending & Validating Smoked Cannabis -- CFN Media," issued earlier today by CFN Media, we are advised by the company that the Tetra Bio-Pharma Inc. ticker in the first paragraph should read "(OTCQB: TBPMF)" rather than "(OTC: GRPOF)" as originally issued.  Complete corrected text follows.

Tetra Bio-Pharma: Defending & Validating Smoked Cannabis -- CFN Media

2017-07-06 marketwired
SEATTLE, WA--(Marketwired - Jul 6, 2017) - CFN Media Group ("CannabisFN"), the leading creative agency and digital media network dedicated to legal cannabis, announces publication of an exclusive interview and article discussing Tetra Bio-Pharma Inc. (CNSX: TBP) (OTC: GRPOF) and its clinical approach to defending the use of dried marijuana to treat patients in Canada.

Tetra Bio-Pharma Strengthens its Position on Bringing Marijuana to Patients in a Form Acceptable to Health Care Professionals

2017-07-05 marketwired
OTTAWA, ONTARIO--(Marketwired - July 5, 2017) - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(OTCQB:TBPMF), today announced that it has strengthened its position on bringing marijuana to patients in the form of a prescription drug. Tetra has become a world leader in the field of cannabis drug development and its PPP001 dried cannabis drug was covered in the Global Pain Management Drugs Market analysis report published by Azoth Analytics in May 2017.

Tetra Bio-Pharma Expands into $25 Billion Veterinary Market -- CFN Media

2017-06-29 marketwired
SEATTLE, WA--(Marketwired - Jun 29, 2017) - CFN Media Group ("CannabisFN"), the leading creative agency and media network dedicated to legal cannabis, announces publication of an article that covers Tetra Bio-Pharma Inc.'s (CSE: TBP) (OTCQB: TBPMF) move into the veterinary market.

Tetra Bio-Pharma Expands Focus of Commercialization Activities into the Lucrative Veterinary Market

2017-06-28 marketwired
OTTAWA, ONTARIO--(Marketwired - June 28, 2017) - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(OTCQB:TBPMF), announced today that it will also commercialize novel cannabinoid based formulations for the treatment of pet conditions.

Tetra Bio-Pharma Appoints Aphria CFO, Mr. Carl Merton to the Board of Directors

2017-06-14 marketwired
OTTAWA, ONTARIO--(Marketwired - June 14, 2017) - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(OTCQB:TBPMF) today announced that it has appointed Mr. Carl A. Merton to the Board of Directors, effective immediately.

Tetra Bio-Pharma Announces UNB Cannabis Health Research Chair

2017-06-13 marketwired
OTTAWA, ONTARIO--(Marketwired - June 13, 2017) - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(OTCQB:TBPMF) and The New Brunswick Health Research Foundation are investing a combined $1 million, $500,000 each over five years to establish a Health Research Chair in Cannabis at the University of New Brunswick (UNB).

Tetra Bio-Pharma: First Clinical Trial of Natural Cannabis for Cancer Pain Entering Phase III -- CFN Media

2017-06-08 marketwired
SEATTLE, WA--(Marketwired - Jun 8, 2017) - CFN Media Group ("CannabisFN"), the leading creative agency and digital media network dedicated to legal cannabis, announces publication of an article discussing Tetra Bio-Pharma Inc. (CSE: TBP) (OTCQB: TBPMF) and its recent progress in bringing its smokeable marijuana therapeutic to market.

Tetra Bio-Pharma Announces the Completion of its Phase 1 Safety Report to Health Canada and Launches the Preparation of a Phase III Clinical Trial for PPP001 with Sante Cannabis

2017-06-07 marketwired
OTTAWA, ONTARIO--(Marketwired - June 7, 2017) - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(OTCQB:TBPMF), and PhytoPain Pharma (PPP), a subsidiary of Tetra Bio-Pharma, is pleased to announce that it has submitted a report on the safety and pharmacokinetics of PPP001 (smokeable marijuana) to Health Canada. The Company is also launching the preparation of a Phase III clinical trial in collaboration with Québec's leading medical cannabis clinic, Santé Cannabis.

Tetra Bio-Pharma Strengthens its Board with the Appointment of Dr. Bill Cheliak

2017-05-30 marketwired
OTTAWA, ONTARIO--(Marketwired - May 30, 2017) - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(OTCQB:TBPMF), today announced that it has appointed Dr. W.M. (Bill) Cheliak to the Board of Directors effective immediately.

Tetra Bio-Pharma Signs Definitive Agreement for Two Products with Panag Pharma

2017-05-23 marketwired
OTTAWA, ONTARIO--(Marketwired - May 23, 2017) - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(OTCQB:TBPMF), announced today it has signed a definitive agreement with Panag Pharma Inc. for the development and commercialization of novel cannabinoid based formulations for the treatment of pain and inflammation. Combined total market potential of both products in the USA in 2014 is estimated over US$5.

Tetra Bio-Pharma Files Patent for the Treatment of Cancer and Ocular Disease

2017-05-17 marketwired
OTTAWA, ONTARIO--(Marketwired - May 17, 2017) - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(OTCQB:GRPOF), today announced that Tetra has submitted a provisional patent application with the U.S. patent and trademark office for a pharmaceutical drug formulation to treat various forms of cancer and ocular disease.

IntelGenx Technologies' (IGXT) CEO Dr. Horst Zerbe on Q1 2017 Results - Earnings Call Transcript

2017-05-12 seekingalpha
[Call Starts Abruptly] …on the line are Dr. Horst Zerbe, IntelGenx’s President and CEO; and Andre Godin, our Executive Vice President and CFO.

Tetra Bio-Pharma Strengthens Management Team

2017-05-10 marketwired
OTTAWA, ONTARIO--(Marketwired - May 10, 2017) - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (CSE:TBP)(CSE:TBP.CN)(OTCQB:GRPOF), today announced that it has strengthened its management team with the appointment of Robert Bechard to the position of Vice President, Finance and Business Development, effective today, May 10, 2017.

Tetra Bio-Pharma Plays to Its Strengths with Pharma Approach, Plus Exclusive Interview -- CFN Media

2017-05-04 marketwired
SEATTLE, WA--(Marketwired - May 4, 2017) - CFN Media Group ("CannabisFN"), the leading creative agency and digital media network dedicated to legal cannabis, announces publication of an exclusive interview and article discussing Tetra Bio-Pharma Inc. (CSE: TBP) (OTCQB: GRPOF) and its transition to a pharmaceutical-like approach to the cannabis industry. The interview is with Dr. Guy Chamberland, Tetra's Chief Science Officer.

Aphria Inc. Canadian Cannabis Producer Raises C$100 Million in Capital Analyst Report

2017-04-25 accesswire
NEW YORK, NY / ACCESSWIRE / April 25, 2017 / Traders News Source, a leading independent equity research and corporate access firm focused on small and micro-cap public companies is issuing a comprehensive report with no obligation on Aphria Inc. (OTCQB: APHQF), a Canadian company that produces, supplies, and sells medical cannabis. On April 20, 2017, the company announced that it had raised C$100 million in financing.